Aurobindo Pharma completed the acquisition of seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc, a US-based global branded oncology company by Acrotech Biopharma. Aurobindo will pay an upfront purchase price of $160 million in cash plus up to $140 million on achieving milestones.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/2tLQLcg
0 comments:
Post a Comment